The sertindole safety survey: A retrospective analysis under a named patient use programme in Europe

BMC Psychiatry

Volumn 8, Issue , 2008, Pages

  Lançon, Christophe ^a   Toumi, Mondher ^b   Sapin, Christophe ^c   Hansen, Karina ^c  

^a HÔPITAL SAINTE MARGUERITE   (France)

^b UNIVERSITÉ LYON 1   (France)

^c Lundbeck   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; SERTINDOLE; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE;

ADULT; ARTICLE; CARCINOMA; CONVULSION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; ECG ABNORMALITY; EUROPE; FEMALE; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HUMAN; INTOXICATION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MESENTERIC ARTERY OCCLUSION; MORTALITY; NEUROLEPTIC MALIGNANT SYNDROME; PRESCRIPTION; QT PROLONGATION; SCHIZOPHRENIA; SUICIDE ATTEMPT; SYNCOPE; TORSADE DES POINTES; BRAIN DISEASE; CHEMICALLY INDUCED DISORDER; CHRONIC DISEASE; HOSPITALIZATION; LONG QT SYNDROME; PROGRAM DEVELOPMENT; PROSPECTIVE STUDY; PSYCHOLOGICAL ASPECT; PSYCHOSIS; QUESTIONNAIRE; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; ANTIPSYCHOTIC AGENTS; BRAIN DISEASES; CHRONIC DISEASE; EUROPE; FEMALE; HUMANS; IMIDAZOLES; INDOLES; LONG QT SYNDROME; MALE; PROGRAM DEVELOPMENT; PROSPECTIVE STUDIES; PSYCHOTIC DISORDERS; QUESTIONNAIRES; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 48949085884     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-8-57     Document Type: Article

References (23)

1. Jablensky A Sartorius N Ernberg G Anker M Korten A Cooper JE Day R Bertelsen A Schizophrenia: Manifestations, incidence and course in different cultures - a World Health Organization ten-country study Psychol Med Monogr Suppl 1992, 20:1-97 1565705
2. McGrath J Saha S Welham J El Saadi O MacCauley C Chant D A systematic review of the incidence of schizophrenia: The distribution of rates and the influence of sex, urbanicity, migrant status, and methodology BMC Med 2004, 2:13 421751 15115547 10.1186/1741-7015-2-13
3. National Institute of Mental Health Schizophrenia 2002
4. Saha S Chant D Welham J McGrath J A systematic review of the prevalence of schizophrenia PLoS Med 2005, 2.5:e141 10.1371/journal.pmed.0020141
5. Jablensky A Epidemiology of schizophrenia: The global burden of disease and disability Eur Arch Psychiatry Clin Neurosci 2000, 250:274-285 10.1007/s004060070002 11153962
6. National Institute of Mental Health Mental Health: A Report of the Surgeon General National Institute of Mental Health 1999, 494.
7. World Health Organization Regional Office for South-Est Asia. Schizophrenia: Youth's Greatest Disabler Health & Behavior. Facts and Figures Word Health Organization 2004
8. Jablensky A Epidemiology of schizophrenia: A European perspective Schizophr Bull 1986, 12:52-73 3961427
9. Allison DB Mentore JL Heo M Chandler LP Cappelleri JC Infante MC Weiden PJ Antipsychotic-induced weight gain: A comprehensive research synthesis Am J Psychiatry 1999, 156:1686-1696 10553730
10. Henderson DC Calgliero E Copeland PM Borba CP Evins E Hayden D Weber MT Anderson EJ Allison B David DB Daley TB Schoenfeld D Goff DC Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: Frequently sampled intravenous glucose tolerance test and minimal model analysis Arch Gen Psychiatry 2005, 62:19-28 10.1001/archpsyc.62.1.19 15630069
11. Koro CE Fedder DO L'Italien GJ Sheila Weiss S Magder LS Kreyenbuhl J Revicki D Buchanan RW An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipedemia in schizophrenic patients Arch Gen Psychiatry 2002, 59:1021-1026 10.1001/ archpsyc.59.11.1021 12418935
12. Liberman JA Stroup TS McEvoy JP Swartz MS Rosenheck RA Perkins DO Keefe RSE Davis SM Davis CE Lebowitz BD Severe J Hsiao JK for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia New Engl J Med 2005, 353(12):1209-1223 10.1056/ NEJMoa051688 16172203
13. Azorin JM Strub N Loft H A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia Int Clin Psychopharmacol 2006, 21:49-56 10.1097/ 01.yic.0000177020.26311.a7 16317317
14. Lindström E Levander S Sertindole: Efficacy and safety in schizophrenia Expert Opin Pharmacother 2006, 7(13):1825-1834 10.1517/ 14656566.7.13.1825 16925508
15. Nabulsi AA Braus AJ Mack RJ Sebree T Holgate K 1996 Reduction of hospital days in sertindole treated patients: One year findings [poster 566] New research program and abstracts from the American Psychiatric Association, Washington DC
16. Kasper S Quiner S Pezawas L A review of the benefit: Risk profile of sertindole International Journal of Psychiatry in Clinical Practice 1998, 2(2):S59-S64
17. Moore N Hall G Sturkenboom M Mann R Lagnaoui R Begaud B Biases affecting the proportional reporting ratio (PPR) in spontaneous reports pharmacovigilance databases: The example of sertindole Pharmacoepidemiol Drug Saf 2003, 12:271-81 10.1002/pds.848 12812006
18. Bingefors K Isacson D Lindström E Dosage patterns of antipsychotic drugs for the treatment of schizophrenia in Swedish ambulatory clinical practice - a highly individualized therapy Nord J Psychiatry 2003, 57:263-269 10.1080/08039480307280 12888400
19. McCue RE Waheed R Urcuyo L Polypharmacy in Patients with Schizophrenia J Clin Psychiatry 2003, 64(9):984-988 14628972
20. Gilbert PL Harris MJ McAdams LA Jeste DV Neuroleptic withdrawal in schizophrenic patients. A review of literature Arch Gen Psychiatry 1995, 52(3):173-88 7872841
21. Baldessarini RJ Viguera AC Neuroleptic withdrawal in schizophrenic patients Arch Gen Psychiatry 1995, 52(3):2-192
22. Moore N Higher cardiovascular mortality with sertindole in ADROIT: A signal not confirmed Int J Psy Clin Practice 2002, 6(Suppl 1):S3-S9 10.1080/13651500210340
23. Waddington JL Youssef HA Kinsella A Mortality in schizophrenia Br J Psychiatry 1998, 173:325-329 9926037